Certain Blood Protein Levels May Predict Mortality Risk After Sudden Disease Worsening in IPF, Study Suggests

Lung Therapeutics announced that it has raised $36 million in Series C financing to fund two projects, including a healthy volunteer Phase 1 clinical trial testing LTI-03, an experimental therapy for idiopathic pulmonary fibrosis (IPF). Currently approved therapies for IPF can slow disease progression, but cannot restore…

As a patient living with idiopathic pulmonary fibrosis (IPF), I can’t count the number of times that close friends and family members have asked me to describe what this disease feels like. While I do my best to share my experience with IPF, I’ve been unsatisfied with the explanations I’ve…

This week, the world lost a champion. On June 3, 2019, Kim Fredrickson, a stoic and heroic inspiration to so many people living with pulmonary fibrosis (PF), died after nearly four months in the intensive care unit at UCSF Medical Center, where she was awaiting a life-saving…

After being diagnosed with a devastating disease like idiopathic pulmonary fibrosis (IPF), life tends to come to a momentary halt. I was OK mentally after the initial diagnosis, but I then contracted respiratory syncytial virus (RSV) in January 2015. This secondary illness, caused by my IPF diagnosis,…

Plans for a Phase 2 clinical trial of brilaroxazine, the lead candidate by Reviva Pharmaceuticals to treat idiopathic pulmonary fibrosis (IPF), were the focus of a recent and successful meeting between company officials and the U.S. Food and Drug Administration (FDA), Reviva announced. During this pre-Investigational New Drug (IND) Application meeting, the regulatory…